Mostrar el registro sencillo del ítem
Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia
dc.contributor.author | Giménez, N. | |
dc.contributor.author | Martínez Trillos, A. | |
dc.contributor.author | Montraveta, A. | |
dc.contributor.author | Suárez Puente, Xosé Antón | |
dc.contributor.author | López Otín, Carlos | |
dc.date.accessioned | 2019-08-21T07:34:17Z | |
dc.date.available | 2019-08-21T07:34:17Z | |
dc.date.issued | 2019 | |
dc.identifier.citation | Haematologica, 104(3), p. 576-586 (2019); doi:10.3324/haematol.2018.196931 | |
dc.identifier.issn | 0390-6078 | |
dc.identifier.uri | http://hdl.handle.net/10651/52304 | |
dc.description.sponsorship | This study was supported by the Ministerio de Economía y Competitividad, Grant n. SAF2015-67633-R ,and PI16/00420 which are part of Plan Nacional de I+D+I and are co-financed by the European Regional Development Fund (FEDER-“Una manera de hacer Europa”) and the CERCA program from Generalitat Catalunya. European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement n. 306240; Generalitat de Catalunya Suport Grups de Recerca AGAUR 2017-SGR1009, and Departament de Salut (SLT002-16-00350), Instituto de Salud Carlos III (ISCIII) International Cancer Genome Consortium for Chronic Lymphocytic Leukemia (ICGC-CLL Genome Project), and project PM15/00007, which is part of Plan Nacional de I+D+I and are co-financed by FEDER. NG is a recipient of a predoctoral fellowship from Agaur and EC is an Academia Researcher of the "Institució Catalana de Recerca i Estudis Avançats" (ICREA) of the Generalitat de Catalunya. | |
dc.description.statementofresponsibility | Giménez, N., Martínez-Trillos, A., Montraveta, A., Lopez-Guerra, M., Rosich, L., Nadeu, F., Valero, J.G., Aymerich, M., Magnano, L., Rozman, M., Matutes, E., Delgado, J., Baumann, T., Gine, E., González, M., Alcoceba, M., Terol, M.J., Navarro, B., Colado, E., Payer, A.R., Puente, X.S., López-Otín, C., Lopez-Guillermo, A., Campo, E., Colomer, D., Villamor, N. | |
dc.format.extent | p. 576-586 | |
dc.language.iso | eng | |
dc.relation.ispartof | Haematologica, 104 | |
dc.rights | © 2019 Ferrata Storti Foundation | |
dc.rights | CC Reconocimiento - No Comercial 4.0 Internacional | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | |
dc.source | Scopus | |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063064850&doi=10.3324%2fhaematol.2018.196931&partnerID=40&md5=f7b590064a0c26d1f8d5c8d1e7a2743d | |
dc.title | Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia | |
dc.type | journal article | |
dc.identifier.doi | 10.3324/haematol.2018.196931 | |
dc.relation.projectID | MINECO/SAF2015-67633-R | |
dc.relation.projectID | MINECO/PI16/00420 | |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/FP7/306240 | |
dc.relation.projectID | ISCIII/FEDER/PM15/00007 | |
dc.relation.publisherversion | http://dx.doi.org/10.3324/haematol.2018.196931 | |
dc.rights.accessRights | open access | |
dc.type.hasVersion | VoR |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Artículos [34459]
-
Bioquímica y Biología Molecular [265]
-
Investigaciones y Documentos OpenAIRE [7529]
Publicaciones resultado de proyectos financiados con fondos públicos